The Dexcom G7 Continuous Glucose Monitoring (CGM) System is the most accurate CGM for reliable therapy decisions that lead to proven results.1,4-8 Dexcom G7 is proven to lower A1C and increase time in range for patients with diabetes.4-8
Company Background
Dexcom, Inc. empowers people to take control of health through innovative CGM systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
Product Overview
Dexcom G7 is the simple CGM for effortless diabetes management. The low-profile, all-in-one wearable sensor warms up in only 30 minutes, two times faster than any other CGM on the market.* Users will receive realtime glucose readings automatically on their compatible smart device† or Dexcom receiver, no fingersticks‡ required. Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels with a predictive low alert that can recognize potentially dangerous hypoglycemic incidents before they occur.
Dexcom G7 is clinically proven to lower A1C, demonstrating an A1C reduction >1% after 12 weeks,4,5,8 increase time in range,4-8 reduce hyperand hypoglycemia,6,9,10,§ increase adherence,11 and improve quality of life.4-8,12 Dexcom G7 is the preferred CGM of national payors on the pharmacy benefit.13,|| As the most covered CGM brand,14,¶ Dexcom requires only one prescription for Dexcom G7 to be sent directly to the pharmacy for a quick, simple start and low out-of-pocket costs with most patients paying $0 at the pharmacy.14,#
Dexcom G7 is an integrated CGM (iCGM) indicated for the widest age range15 and across diabetes types (type 1, type 2, and gestational diabetes) and treatment types (basal insulin, noninsulin, glucagon-like peptide-1). No other CGM system is more affordable than Dexcom G7 for Medicare patients.** For more information on affordability programs, please visit dexcom.com/savings.
Features & Options
Dexcom G7 is the most accurate CGM powering automated insulin delivery (AID) systems:2,3
• Two times faster warmup than any other CGM.*
• Dexcom CGM is the only brand currently powering AID systems that allows up to 10 people in your circle to follow you.
• The first and only CGM with no fingersticks from day one.‡
• Only CGM with app features that help protect from severe hypoglycemia and diabetic ketoacidosis.
• Our smallest CGM sensor15 currently powering AID systems.
• The Dexcom CGM brand has over 1.7 million patient-years on AID systems.14
• Dexcom G7 is the most connected CGM, connecting to Tandem, Lilly Tempo, Insulet Omnipod, and Beta Bionics devices.
Testimonials
Dexcom G7 is the simple and most affordable CGM brand:14,||
• 96% of patients say Dexcom G7 is easy to use.1
• More than eight out of 10 Dexcom users stay on product after one year.14
• Dexcom is #1 in patient satisfaction,16,†† adherence,17 and retention.14,††
• Dexcom is the preferred CGM of national payors on the pharmacy benefit.13,||
• 90% of commercial patients have coverage at the pharmacy and the majority do not have a manual prior authorization.
• Most Medicare Advantage patients have coverage at the pharmacy.14,# Savings programs are available for patients without CGM coverage.
Ordering Information
To order, please contact your pharmacy wholesale partner. Dexcom G7 is available to order from all major wholesalers.
*Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
†Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility.
‡Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
§Hyperglycemia >250 mg/dL.
||Individual coverage may vary depending on commercial pharmacy coverage benefits.
#Individual pricing may vary depending on insurance coverage.
**Under Medicare’s DME fee schedule, reimbursement and coinsurance for CGM using CPT codes A4239 and E2103, are the same, regardless of CGM brand.
††Based on a comparison in NPS scores across major CGM brands.
‡‡Patients using insulin with paid sensor claims at 12 months.
1 Dexcom, data on file, 2023. 2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. https://www.accessdata. fda.gov/cdrh_docs/reviews/K213919.pdf 3 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www. accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 9 Lind N, et al. Diabetes Care. 2024;47(5):881-889. 10 Wilmot E. Dexcom G7: Unique Features and Correlational Improvements in Glycemic Control. Presented at the 16th International ATTD Conference on February 23, 2023. 11 Nemlekar PM, et al. Diabetes Ther. 2024;15(3):639-648. 12 Gilbert TR, et al. Diabetes Technol Ther.
2021;23(S1):S35-S39. 13 Managed Markets Insights & Technology, LLC. MMIT Analytics April-June 2024. 14 Dexcom, data on file, 2024. 15 Dexcom G7 User Guide, 2023. 16 DQ&A Q1 2023 Patient Perspectives. 17 Seagrove Patient Perspectives 2021.
Dexcom, Inc. is the leader in transforming diabetes care and management by providing continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes.
